Encyclopedia of Applied Electrochemistry

2014 Edition
| Editors: Gerhard Kreysa, Ken-ichiro Ota, Robert F. Savinell

Gene Electrotransfer for Clinical Use

Reference work entry
DOI: https://doi.org/10.1007/978-1-4419-6996-5_268

Introduction

Gene therapy refers to the introduction of nucleic acids, e.g., DNAs or RNAs, into the cells of target tissues with a therapeutic purpose. Gene therapy can be applied as a gene replacement therapy or mutation compensation (e.g., replacement of mutated oncogene), gene immunopotentiation (e.g., introduction of cytokines and co-stimulatory molecules), a molecular chemotherapy (e.g., gene directed enzyme/prodrug therapy) in cancer gene therapy, and gene vaccination (e.g., introduction of specific antigen).

The main faltering block to effective and broader use of gene therapy remains the effective delivery of therapeutic gene to target tissue. In general, gene delivery systems can be divided in viral and nonviral delivery. Among viral delivery vectors, adenoviral and retroviral vectors are the most advanced [ 1, 2]. Nonviral delivery systems are based on chemical vectors (e.g., liposomes, dendrimers, nanoparticles) or physical methods of delivery (e.g., electroporation,...
This is a preview of subscription content, log in to check access

References

  1. 1.
    Warnock JN, Daigre C, Al-Rubeai M (2011) Introduction to viral vectors. Methods Mol Biol 737:1–25Google Scholar
  2. 2.
    Mauro G (2010) Methods for gene delivery. In: Giacca M (ed) Gene therapy. Springer, BerlinGoogle Scholar
  3. 3.
    Cemazar M, Golzio M, Rols MP, Sersa G, Teissie J (2006) Electrically-assisted nucleic acid delivery in vivo: Where do we stand? Review. Curr Pharm Des 12(29):3817–3825Google Scholar
  4. 4.
    Kay MA (2011) State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 12:316–328Google Scholar
  5. 5.
    Heller LC, Heller R (2010) Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 10:312–317Google Scholar
  6. 6.
    Escoffre JM, Teissié J, Rols MP (2010) Gene transfer: how can the biological barriers be overcome? J Membr Biol 236:61–74Google Scholar
  7. 7.
    Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M (2008) Electrochemotherapy in treatment of tumours. EJSO 34:232–240Google Scholar
  8. 8.
    Rosazza C, Phez E, Escoffre JM, Cézanne L, Zumbusch A, Rols MP (2012) Cholesterol implications in plasmid DNA electrotransfer: evidence for the involvement of endocytotic pathways. Int J Pharm 423:134–143Google Scholar
  9. 9.
    Cemazar M, Wilson I, Dachs GU, Tozer G, Sersa G (2004) Direct visualization of electroporation-assisted in vivo gene delivery to tumors using intravital microscopy – spatial and time dependent distribution. BMC Cancer 4:81Google Scholar
  10. 10.
    Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26:5896–5903Google Scholar
  11. 11.
    Pavlin D, Cemazar M, Coer A, Sersa G, Pogacnik A, Tozon N (2011) Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiol Oncol 45:31–39Google Scholar
  12. 12.
    Neumann E, Schaeferridder M, Wang Y, Hofschneider PH (1982) Gene transfer into mouse lypoma cellls by electroporation in high electric fields. EMBO J 1:841–845Google Scholar
  13. 13.
    Titomirov AV, Sukharev S, Kistanova E (1991) In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta 1088:131–134Google Scholar
  14. 14.
    Niu GL, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W et al (1999) Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59:5059–5063Google Scholar
  15. 15.
    Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K, Kurata T et al (2000) Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18:3214–3222Google Scholar
  16. 16.
    Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, Billard V, Geertsen PF, Larkin JO, Miklavcic D, Pavlovic I et al (2006) Electrochemotherapy – an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 4:3–13Google Scholar
  17. 17.
    International Clinical Trials registry Platform (2012) Search Portal. http://apps.who.int/trialsearch/default.aspx. Accessed 17 Apr 2012
  18. 18.
    Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Stevenson F, Ottensmeier CH (2009) DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 20:1269–1278Google Scholar
  19. 19.
    van Drunen Littel-van den Hurk S, Hannaman D (2010) Electroporation for DNA immunization: clinical application. Expert Rev Vaccines 9:503–517Google Scholar
  20. 20.
    Sardesai NY, Weiner DB (2011) Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 23:421–429Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Experimental OncologyInstitute of Oncology LjubljanaLjubljanaSlovenia